| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | RLAY | Common Stock | Award | $17.8K | +1.66K | +0.52% | $10.68 | 320K | Jun 30, 2023 | Direct | F1, F2, F3 |
| transaction | RLAY | Common Stock | Sale | -$2.04K | -244 | -0.08% | $8.38 | 318K | Sep 27, 2023 | Direct | F4, F5, F6 |
| Id | Content |
|---|---|
| F1 | The shares were acquired under the Relay Therapeutics, Inc. 2020 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). The reporting person is voluntarily reporting this transaction. |
| F2 | In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on June 30, 2023. |
| F3 | Includes 290,341 shares underlying restricted stock units ("RSUs"). |
| F4 | Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 992 shares of RSUs on September 26, 2023. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs. |
| F5 | Prior to the reported transaction, the amount of securities beneficially owned by the reporting person was 318,470, with 284,835 shares underlying RSUs. |
| F6 | Includes 283,843 shares underlying RSUs. |
Title: Chief Corporate Development Officer